Priya Dayananth

8.5k total citations
9 papers, 760 citations indexed

About

Priya Dayananth is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Priya Dayananth has authored 9 papers receiving a total of 760 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Oncology and 2 papers in Cell Biology. Recurrent topics in Priya Dayananth's work include Cancer-related Molecular Pathways (4 papers), Melanoma and MAPK Pathways (3 papers) and PI3K/AKT/mTOR signaling in cancer (1 paper). Priya Dayananth is often cited by papers focused on Cancer-related Molecular Pathways (4 papers), Melanoma and MAPK Pathways (3 papers) and PI3K/AKT/mTOR signaling in cancer (1 paper). Priya Dayananth collaborates with scholars based in United States, United Kingdom and Germany. Priya Dayananth's co-authors include Alexander Kamb, Steven Stone, Sean V. Tavtigian, Ping Jiang, Godefridus J. Peters, David Parry, Harold L. Katcher, Lisa Cannon‐Albright, Jane Weaver-Feldhaus and Alexander Wong and has published in prestigious journals such as Oncogene, Biochemical Journal and Journal of Medicinal Chemistry.

In The Last Decade

Priya Dayananth

9 papers receiving 744 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Priya Dayananth United States	9	560	434	138	99	60	9	760
Wilhelm Henning Germany	6	662 1.2×	419 1.0×	130 0.9×	87 0.9×	61 1.0×	6	764
Naoe Taira Japan	11	544 1.0×	297 0.7×	127 0.9×	47 0.5×	66 1.1×	13	737
Kathleen A. Scorsone United States	15	674 1.2×	350 0.8×	178 1.3×	103 1.0×	153 2.5×	18	1.0k
Edith A. Leonhardt United States	8	587 1.0×	253 0.6×	172 1.2×	74 0.7×	55 0.9×	11	764
Luis A. Martinez United States	10	601 1.1×	275 0.6×	218 1.6×	67 0.7×	40 0.7×	13	755
Dimitri Semizarov United States	11	792 1.4×	240 0.6×	237 1.7×	115 1.2×	71 1.2×	17	972
Huiping Pei United States	10	606 1.1×	263 0.6×	114 0.8×	60 0.6×	49 0.8×	10	774
Nicholas T. Woods United States	17	614 1.1×	236 0.5×	137 1.0×	110 1.1×	93 1.6×	40	858
Liz J. Valente Australia	12	680 1.2×	443 1.0×	180 1.3×	47 0.5×	84 1.4×	13	884
Rebecca A. Dagg Australia	12	707 1.3×	259 0.6×	126 0.9×	58 0.6×	56 0.9×	17	1.0k

Countries citing papers authored by Priya Dayananth

Since Specialization

Citations

This map shows the geographic impact of Priya Dayananth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Priya Dayananth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Priya Dayananth more than expected).

Fields of papers citing papers by Priya Dayananth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Priya Dayananth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Priya Dayananth. The network helps show where Priya Dayananth may publish in the future.

Co-authorship network of co-authors of Priya Dayananth

This figure shows the co-authorship network connecting the top 25 collaborators of Priya Dayananth. A scholar is included among the top collaborators of Priya Dayananth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Priya Dayananth. Priya Dayananth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Jha, Sharda, Erick J. Morris, Alan Hruza, et al.. (2016). Dissecting Therapeutic Resistance to ERK Inhibition. Molecular Cancer Therapeutics. 15(4). 548–559. 39 indexed citations

2.

Singh, Sheo B., Priya Dayananth, Carl J. Balibar, et al.. (2015). Kibdelomycin Is a Bactericidal Broad-Spectrum Aerobic Antibacterial Agent. Antimicrobial Agents and Chemotherapy. 59(6). 3474–3481. 37 indexed citations

3.

Deng, Yongqi, Gerald W. Shipps, Alan Cooper, et al.. (2014). Discovery of Novel, Dual Mechanism ERK Inhibitors by Affinity Selection Screening of an Inactive Kinase. Journal of Medicinal Chemistry. 57(21). 8817–8826. 38 indexed citations

4.

Gheyas, Ferdous, Priya Dayananth, Weihong Jin, et al.. (2004). Analysis of the ERK1,2 transcriptome in mammary epithelial cells. Biochemical Journal. 381(3). 635–644. 24 indexed citations

5.

Wong, Alexander, Patricia A. Ormonde, Ralph Pero, et al.. (1998). Characterization of a carboxy-terminal BRCA1 interacting protein. Oncogene. 17(18). 2279–2285. 139 indexed citations

6.

Stone, Steven, Priya Dayananth, & Alexander Kamb. (1996). Reversible, p16-mediated cell cycle arrest as protection from chemotherapy.. PubMed. 56(14). 3199–202. 40 indexed citations

7.

Jiang, Ping, Steven Stone, Roger A. Wagner, et al.. (1995). Comparative analysis of Homo sapiens and Mus musculus cyclin-dependent kinase (CDK) inhibitor genes P16 (MTS1) and P15 (MTS2). Journal of Molecular Evolution. 41(6). 795–802. 16 indexed citations

8.

Stone, Steven, Priya Dayananth, Ping Jiang, et al.. (1995). Genomic structure, expression and mutational analysis of the P15 (MTS2) gene.. PubMed. 11(5). 987–91. 91 indexed citations

9.

Stone, Steven, Ping Jiang, Priya Dayananth, et al.. (1995). Complex structure and regulation of the P16 (MTS1) locus.. PubMed. 55(14). 2988–94. 336 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact